BioStar Capital — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
AVS develops the Pulse IVL system, a medical device for treating calcified arterial disease using a unique mechanism of action for improved deliverability in peripheral and coronary applications.
BiotechDeep TechHealthtechMedical DevicesAnn Arbor, US
Robert Chisena, Ph.D.(Co-Founder & Chief Technology Officer)Andrew Casey(Executive Officer)inSean Gilligan(Executive Officer)inMark Toland(Executive Officer, Director)Hitinder Gurm, M.D.(Chief Clinical Officer)Robert Chisena(Executive Officer)
Board seatWilliam H. (Hank) KuchemanHank Kucheman· per SEC Form D
Co-investorsBioStar VenturesCorewell Health VenturesID Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




